DUBLIN, Mar. 09, 2015 /PRNewswire/ --Research and Markets
(http://www.researchandmarkets.com/research/thq3sp/dry_eye_syndrome) has announced the addition of the "Dry Eye Syndrome: Clinical Trial Tracker - Subscription" subscription to their offering.
With nearly 300 million dry eye sufferers worldwide, dry eye represents one of the largest ophthalmic indications. It is also known as keratoconjunctivitis sicca.
To date, there is no cure for dry eye syndrome, but there are treatments to control its symptoms. The prevalence of dry eye syndrome primarily increases with age, and has an estimated incidence of 15% in persons over the age of 65 years. A greater risk of acquiring dry eye is also experienced by females, with postmenopausal women being particularly at risk.
In the US alone, the economic burden of dry eye totals USD 3.84 billion in direct annual health care costs. After including the indirect costs of lost productivity, the societal burden of dry eye rises to USD 55.4 billion annually in the US. For patients, the average annual direct cost ranges from USD 678 for patients with mild dry eye to USD 1,267 for severe cases.
If pharmaceuticals and punctual plugs are included, the cost for these patients rises to USD 2,959 annually. Furthermore, dry eye increases lost productivity through both absenteeism and decreased presenteeism, with the former ranging from 8.4 to 14.2 days per year depending on severity and the latter ranging from 91 to 128.2 days per year depending on severity.
The primary objective of this report is to capture details on the various clinical and preclinical trials which are currently underway in the field of dry eye. We have identified a number of such trials which are taking place across multiple geographies.
For each specific trial the following information is provided:
- Trial Objective
- Manufacturer / Licensee
- Treatment Target
- Mechanism of Action
- Sponsor / Collaborator
- Trial Phase
- Trial Status
- Start Date
- End Date
- Age Group
- Inclusion Criteria
- Exclusion Criteria
- Study Design
- Primary Endpoint
- Secondary Endpoint
- Treatment Arms
- Route of Administration
- Trial Results (if known)
Companies Mentioned: Sample of Companies that Feature
- Bristol Eye Hospital
- Eleven Biotherapeutics
- ESBATech AG
- Eye and ENT Hospital of Fudan University
- I.M. Sechenov First Moscow State Medical University (MSMU)
- Innovative Medical
- Mahidol University
- Massachusetts Eye and Ear Infirmary
- Medical University of South Carolina
- National Institutes of Health Clinical Center (CC)
- Nihon University School of Medicine
- Nippon Medical School
- Novagali Pharma
- R-Tech Ueno, Ltd.
- Rush Medical College
- Santarus, Inc.
- Santen Inc.
- Sylentis, S.A.
- The Catholic University of Korea
- The Helmholtz Moscow Research Institute of Eye Diseases
- Tokai University School of Medicine
- University of Kitasato School of Medicine
- University of Miami
- University of Michigan
- University of Missouri-Columbia
For more information visit http://www.researchandmarkets.com/research/thq3sp/dry_eye_syndrome
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets